Table 3.

Patterns of Invasive Management and Concomitant Therapy Use Stratified by MI Type and Early P2Y12 Antagonist Use

	NSTEMI			STEMI
	Clopidogrel (N=78 559)	Prasugrel (N=11 308)	P Value	Clopidogrel (N=68 617)	Prasugrel (N=21 633)	P Value
Early invasive therapy*	52%	89%	<0.0001	—	—	—
Primary PCI	—	—	—	92%	96%	<0.0001
Drug initiation prior to cath	65%	18%	—	48%	15%	—
Fibrinolytic therapy	—	—	—	14%	10%	<0.0001
CABG	6%	2%	<0.0001	3%	1%	<0.0001
Medically managed	35%	8%	<0.0001	3%	2%	<0.0001
GP IIb‐IIIa*	27%	44%	<0.0001	58%	59%	<0.0001
Bivalirudin	29%	47%	<0.0001	35%	48%	<0.0001

CABG indicates coronary artery bypass graft; DM, diabetes mellitus; MI, myocardial infarction; PCI, percutaneous coronary intervention.

^*Within 48 hours of admission.